ResultsIQ

ResultsIQ › Latest results › Blue Jet Healthcare Limited

Blue Jet Healthcare Limited Q2 FY26 results deck summary

NSE: BLUEJET · BSE: 544009

Results deck of 4 Nov 2025, summarised by AI from the filing.

Revenue from operations ₹1,655 mn in Q2 FY26, down 53.4% QoQ from ₹3,548 mn and 20.5% YoY from ₹2,083 mn.

Key takeaways

  1. Q2 revenue Revenue from operations ₹1,655 mn in Q2 FY26, down 53.4% QoQ from ₹3,548 mn and 20.5% YoY from ₹2,083 mn.
  2. Q2 PAT PAT ₹521 mn in Q2 FY26, down 42.8% QoQ from ₹912 mn and 10.6% YoY from ₹583 mn.
  3. Gross margin Gross margin rose to 65.0% in Q2 FY26 from 48.4% in Q1 FY26 due to inventory change and overhead allocation.
  4. Risk Q2 revenue decline due to lower sales in PI segment entirely from de-stocking of channel inventory.

Original filing on BSE

Blue Jet Healthcare Limited Q1 FY27 results

As filed: Revenue ₹293 cr (−17% year on year), EBITDA ₹98.1 cr (−20% year on year), PAT ₹78.3 cr (−14% year on year), EBITDA margin 33.5% (−90 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹235 cr (−31% year on year), EBITDA ₹71.3 cr (−49% year on year), PAT ₹64.3 cr (−42% year on year), EBITDA margin 30.4% (−1,000 bps). Score 15 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Other income 26% of PBT. Share price after the results: +17.2% in 30 days (Nifty 500: +2.1%).
  • Q3 FY26: Revenue ₹192 cr (−39% year on year), EBITDA ₹46.9 cr (−62% year on year), PAT ₹40.2 cr (−59% year on year), EBITDA margin 24.4% (−1,000 bps). Score 14 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Profit fell 23% from last quarter. Share price after the results: −18.8% in 28 days (Nifty 500: −9.6%).
  • Q2 FY26: Revenue ₹165 cr (−21% year on year), EBITDA ₹56.0 cr (−20% year on year), PAT ₹52.0 cr (−10% year on year), EBITDA margin 33.9% (+29 bps). Score 6 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin rose 29 bps year on year. Other income 35% of PBT. Revenue fell 54% from last quarter. Share price after the results: −17.7% in 30 days (Nifty 500: −0.3%).
  • Q1 FY26: Revenue ₹355 cr (+118% year on year), EBITDA ₹122 cr (+184% year on year), PAT ₹91.0 cr (+139% year on year), EBITDA margin 34.4% (+799 bps). Score 85 of 100, Above trend. EBITDA margin rose 799 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 17% from last quarter. Share price after the results: −23.5% in 30 days (Nifty 500: −1.0%).
  • Q4 FY25: Revenue ₹340 cr (+85% year on year), EBITDA ₹140 cr (+164% year on year), PAT ₹110 cr (+182% year on year), EBITDA margin 41.2% (+1,000 bps). Score 100 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +24.0% in 30 days (Nifty 500: +2.5%).
  • Q3 FY25: Revenue ₹318 cr (+90% year on year), EBITDA ₹124 cr (+125% year on year), PAT ₹99.0 cr (+209% year on year), EBITDA margin 39.0% (+606 bps). Score 100 of 100, Above trend. EBITDA margin rose 606 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹208 cr (+15% year on year), EBITDA ₹70.0 cr (+13% year on year), PAT ₹58.0 cr (+21% year on year), EBITDA margin 33.7% (−60 bps). Score 55 of 100, In line with trend. EBITDA margin fell 60 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Blue Jet Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.